Journal of Pain & Palliative Care Pharmacotherapy最新文献_第2页

Comparison of Effectivity and Safety of Olanzapine and Mirtazapine on Cancer-Associated Anorexia and Cachexia in Advanced Oral Cavity Cancer Patients: Prospective, Comparative, Interventional Study. 奥氮平和米氮平治疗晚期口腔癌患者癌症相关性厌食症和恶病质的有效性和安全性比较：前瞻性、对比性、介入性研究。

IF 1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-09-01 Epub Date: 2025-05-01 DOI: 10.1080/15360288.2025.2492801

Yogendra Singhal, Surendra Kumar Pingoliya, Pavan Gaurav R, Sreeharsh Saji, Amit Sharma

{"title":"Comparison of Effectivity and Safety of Olanzapine and Mirtazapine on Cancer-Associated Anorexia and Cachexia in Advanced Oral Cavity Cancer Patients: Prospective, Comparative, Interventional Study.","authors":"Yogendra Singhal, Surendra Kumar Pingoliya, Pavan Gaurav R, Sreeharsh Saji, Amit Sharma","doi":"10.1080/15360288.2025.2492801","DOIUrl":"10.1080/15360288.2025.2492801","url":null,"abstract":"Cancer-associated cachexia-anorexia syndrome (CACS) significantly affects patients' quality of life, leading to weight loss, muscle wasting, and reduced treatment response. This prospective study aimed to evaluate effectiveness of olanzapine versus mirtazapine in managing CACS. Primary objective was to assess their impact on body weight and appetite, while the secondary objective focused on psychological distress and sleep. A total of 152 patients were randomly allocated into two groups of 76 patients each. Group O received Tablet Olanzapine 5 mg/day orally; Group M received Tablet Mirtazapine 15 mg/day orally at bed time. All patients were assessed by using Simplified Nutritional Appetite Questionnaire (SNAQ) score and weight at time of first visit then follow-up visit at 2nd and 4th weeks. At 2nd week, the mean change in SNAQ score was 3.14 in Group M compared to 2.04 in Group O (p = 0.035). By the 4th week, it was 3.86 in Group M and 2.87 in Group O (p = 0.006). Weight changes increased from 45.57 to 46.81 kg in Group M and from 45.97 to 46.90 kg in Group O by 4th week (p ≥ 0.5). Both mirtazapine and olanzapine significantly increased appetite without notable weight gain. Mirtazapine showed stronger effects on appetite, sleep, anxiety, and depression.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"432-441"},"PeriodicalIF":1.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inpatient Nalbuphine Substitution During Intravenous IV Opioid Shortage for Acute Pain in a Community Hospital: A Retrospective Review. 一家社区医院急性疼痛阿片类药物短缺期间住院患者纳布啡替代：回顾性回顾。

IF 1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-09-01 Epub Date: 2025-04-16 DOI: 10.1080/15360288.2025.2491698

Kathryn M Storm, Amanda Mullins, Christopher M Herndon

{"title":"Inpatient Nalbuphine Substitution During Intravenous IV Opioid Shortage for Acute Pain in a Community Hospital: A Retrospective Review.","authors":"Kathryn M Storm, Amanda Mullins, Christopher M Herndon","doi":"10.1080/15360288.2025.2491698","DOIUrl":"10.1080/15360288.2025.2491698","url":null,"abstract":"Nalbuphine's mixed agonist-antagonist activity has historically limited use. This study evaluated the impact of utilizing nalbuphine during admission during a parenteral opioid shortage. A single-center retrospective chart review was performed between January 2018 and June 2018 to compare outcomes between those who received nalbuphine and those who received morphine. The primary outcome was average pain score during admission. Secondary outcomes included: change in parenteral opioid, change in dose, and opioid prescription at discharge. In total, 138 patients, 47 in the nalbuphine group and 91 in the morphine group, were included. Average pain score during admission was 3.97 and 4.13 for nalbuphine and morphine, respectively (p = 0.695). There was no statistically significant change in average pain control on day 1, 2, or last day between groups. In opioid-tolerant patients who inadvertently received nalbuphine, average pain scores were higher compared to the nalbuphine opioid-naïve group, admission (p = 0.003), day 1 (p < 0.001), day 2 (p = 0.016), and last day (p = 0.007). No differences were observed based on sex. No difference in pain scores was observed. Nalbuphine resulted in less pain control in opioid-tolerant patients. Nalbuphine may represent an alternative first-line parenteral opioid in the acute care setting.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"332-337"},"PeriodicalIF":1.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Subcutaneously Administered Anesthetics and Analgesics for Pain Management: An Integrative Review. 皮下注射麻醉药和镇痛药治疗疼痛：综合综述。

IF 1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-09-01 Epub Date: 2025-06-12 DOI: 10.1080/15360288.2025.2516521

Bruno D'Paula Andrade, William Caracas Moreira, Roger Rodrigues da Silva, Ticiane Santana Gomes Santiago, Emilio Carlos Del Massa

{"title":"Subcutaneously Administered Anesthetics and Analgesics for Pain Management: An Integrative Review.","authors":"Bruno D'Paula Andrade, William Caracas Moreira, Roger Rodrigues da Silva, Ticiane Santana Gomes Santiago, Emilio Carlos Del Massa","doi":"10.1080/15360288.2025.2516521","DOIUrl":"10.1080/15360288.2025.2516521","url":null,"abstract":"This article aims to summarize evidence regarding subcutaneously administered anesthetics and analgesics and their effects on pain management. Searches were conducted in September 2023 by a paired review in the MEDLINE database via the Virtual Health Library (BVS) and SCOPUS via Elsevier. Study selection was independently performed by two researchers according to inclusion criteria: primary studies, published in any language, and without temporal restriction. Duplicates, irrelevant studies, and those outside the research scope were excluded, with discrepancies resolved by a third reviewer. The final sample for the review comprised 45 articles, predominantly clinical trials with eligible patients, published between 1982 and 2022. Key drug classes identified in the evaluation of subcutaneous administration for pain management included amide and amino-amide anesthetics, opioids, and adjuvant agents (such as anti-inflammatory drugs, antihypertensives, and catecholamines). Primary advantages noted were reduced postoperative opioid use, effective analgesic control in postoperative settings, adjuvant efficacy in intraoperative settings and invasive exams, fewer cognitive side effects compared to other anesthesia types, decreased coughing, and shorter hospitalization and ambulation times. Disadvantages included subcutaneous bupivacaine's poor adjuvant performance when combined with general anesthesia, tissue necrosis associated with tumescent anesthesia technique, and ambiguity regarding postoperative respiratory function.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"393-402"},"PeriodicalIF":1.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Use of Intravenous Infliximab to Treat Cancer Related Fistulae: A Case Report in Home-Based Palliative Care Improving Quality of Life and Closure. 静脉注射英夫利昔单抗治疗癌症相关瘘管：家庭姑息治疗改善生活质量和闭合的病例报告

IF 1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-09-01 Epub Date: 2025-06-11 DOI: 10.1080/15360288.2025.2517770

Carolina Simões, Miguel Julião, Paula Câmara, Maria João Gomes, Maria Paula Custódio, Inês Goulão

引用次数: 0

Complementary Relief: Reassessing Lavender Oil as an Adjunct in Osteoarthritis Care. 辅助缓解：重新评估薰衣草油在骨关节炎护理中的辅助作用。

IF 1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-09-01 Epub Date: 2025-05-15 DOI: 10.1080/15360288.2025.2504458

Jonathan James O Canete

引用次数: 0

The Complementary Role of Supportive and Palliative Care in Enhancing Bone Marrow Transplant Outcomes. 支持和姑息治疗在提高骨髓移植结果中的互补作用。

IF 1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-09-01 Epub Date: 2025-06-08 DOI: 10.1080/15360288.2025.2512465

Suzanne Hojjat-Assari, Zahra Ebrahimzadeh, Asma Mehrjoo, Haanieh Nasiraei Mir, Shayesteh Kokabi Hamidpour, Mohammad Jahangiri, Seyed Mohammadamin Nejati Niaki, Babak Arjmand

{"title":"The Complementary Role of Supportive and Palliative Care in Enhancing Bone Marrow Transplant Outcomes.","authors":"Suzanne Hojjat-Assari, Zahra Ebrahimzadeh, Asma Mehrjoo, Haanieh Nasiraei Mir, Shayesteh Kokabi Hamidpour, Mohammad Jahangiri, Seyed Mohammadamin Nejati Niaki, Babak Arjmand","doi":"10.1080/15360288.2025.2512465","DOIUrl":"10.1080/15360288.2025.2512465","url":null,"abstract":"Hematopoietic stem cell transplantation is one of the important treatment modalities for a wide range of malignant and nonmalignant hematological disorders, as well as congenital and acquired disorders of the immune system. Through bone marrow transplantation, candidates face unique challenges throughout the treatment process, which can be accompanied by high physical and psychological burdens. To address the challenges, emerging interventions, such as supportive and palliative care, have shown significant potential for improving quality of life, enhancing overall well-being, alleviating pain, and reducing patient symptoms. The integration of supportive and palliative care in all types of bone marrow transplantation has become increasingly crucial throughout all phases of transplantation, including pre-, during, and post. Therefore, there has to be a specialized team available that can provide complete care, from diagnosis to post-transplantation. Supportive and palliative care requires collaboration for their shared efforts in meeting the special needs of the patients, increasing their quality of life, hope, mood, and well-being. Accordingly, supportive and palliative care, as an integral part of the transplant process, provides patients comprehensive care that addresses their physical, emotional, and psychological well-being.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"413-431"},"PeriodicalIF":1.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144248299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Consult and A Myriad Cacophonies. 一个咨询和无数的杂音。

IF 1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-09-01 Epub Date: 2025-05-03 DOI: 10.1080/15360288.2025.2500985

Jyothsna Kuriakose

引用次数: 0

Caregiver Barriers When Assisting with Intrathecal Infusion Systems: A Literature Review. 护理人员在协助鞘内输注系统时的障碍：文献综述。

IF 1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-09-01 Epub Date: 2025-04-26 DOI: 10.1080/15360288.2025.2496525

Qian Yang, Lihua Bao, Huajuan Zhang

{"title":"Caregiver Barriers When Assisting with Intrathecal Infusion Systems: A Literature Review.","authors":"Qian Yang, Lihua Bao, Huajuan Zhang","doi":"10.1080/15360288.2025.2496525","DOIUrl":"10.1080/15360288.2025.2496525","url":null,"abstract":"The widespread implementation of intrathecal infusion systems (IIS) in managing chronic pain underscores the pivotal role of family caregivers in ensuring effective treatment outcomes and enhancing patients' quality of life. We conducted a comprehensive literature search across databases including PubMed, Medline, and Web of Science. Research indicates that family caregivers primarily face barriers such as insufficient professional knowledge, technical difficulties, psychological and emotional strain, and a lack of adequate financial and social support. These challenges can compromise the efficacy of pain management and increase caregivers' burdens. In response, recent studies have concentrated on offering targeted educational programs and training, fostering support networks, and encouraging technological innovations and policy reforms. Such initiatives aim to bolster caregivers' capabilities and alleviate their psychological and financial stress, thereby enhancing the overall effectiveness of pain management strategies. The significance of the review is that it highlights the central role of family carers in chronic pain management and points to the importance of enhancing their caring capacity. Future research directions should include the development of more systematic caregiver support programs, an in-depth exploration of the effectiveness of multidisciplinary collaborative models, and an assessment of the promise of emerging technologies for use in the family caregiving environment.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"374-383"},"PeriodicalIF":1.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of Full Spectrum Cannabis Extracts in the Treatment of Chronic Pain: An Open Label Study. 全谱大麻提取物治疗慢性疼痛的有效性：一项开放标签研究。

IF 1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-09-01 Epub Date: 2025-06-17 DOI: 10.1080/15360288.2025.2517778

Aragon F, Lozada M, Bigatti G, González-José R, Kochen S, McCarthy I

{"title":"Effectiveness of Full Spectrum Cannabis Extracts in the Treatment of Chronic Pain: An Open Label Study.","authors":"Aragon F, Lozada M, Bigatti G, González-José R, Kochen S, McCarthy I","doi":"10.1080/15360288.2025.2517778","DOIUrl":"10.1080/15360288.2025.2517778","url":null,"abstract":"The aim of this work was to assess the effectiveness of full-spectrum cannabis (THC and CBD) extracts as adjuvants in the treatment of chronic pain. This is a prospective, open label, longitudinal study. Major cannabinoids were analyzed in herbal preparations using high performance liquid chromatography (HPLC). Subjects were included when chronic pain diagnosis criteria was met according to physicians' diagnosis. A patient stratification protocol was developed using a visual analogue scale to measure pain, a numerical scale for life quality parameters and a self-administered health survey. Eighty-eight patients aged between 35 and 88 years were included. A significant decrease in both pain and other life quality parameters was observed between time zero and subsequent time intervals, excepting the \"appetite\" variable. Overall, 51 individuals reported a decrease in pain, 38 a decrease in anxiety and 48 in insomnia, with \"decrease\" defined as symptom reduction of 50% or more between the first and last consultation. In addition, 23 subjects reduced or discontinued other analgesics and/or anti-inflammatory drugs during the trial. Adverse effects were mild and reversible. These results are consistent with previous studies, supporting effectiveness and safety of cannabis extracts as adjuvants in the treatment of chronic pain.","PeriodicalId":16645,"journal":{"name":"Journal of Pain & Palliative Care Pharmacotherapy","volume":" ","pages":"346-352"},"PeriodicalIF":1.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond the Prescription: Addressing Accessibility, Stigma, and Education in Buprenorphine Therapy. 超越处方：解决丁丙诺啡治疗的可及性、污名和教育问题。

IF 1

Journal of Pain & Palliative Care Pharmacotherapy Pub Date : 2025-09-01 Epub Date: 2025-04-07 DOI: 10.1080/15360288.2025.2488845

Jonathan James O Canete

引用次数: 0